These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33301778)

  • 41. The appropriate use of fecal immunochemical testing.
    Forbes N; Hilsden RJ; Heitman SJ
    CMAJ; 2020 Jan; 192(3):E68. PubMed ID: 31959657
    [No Abstract]   [Full Text] [Related]  

  • 42. Navigating the storm of COVID-19 for patients with suspected bowel cancer.
    D'Souza N; Abulafi M
    Br J Surg; 2020 Jun; 107(7):e204. PubMed ID: 32400893
    [No Abstract]   [Full Text] [Related]  

  • 43. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system.
    Singal AG; Gupta S; Tiro JA; Skinner CS; McCallister K; Sanders JM; Bishop WP; Agrawal D; Mayorga CA; Ahn C; Loewen AC; Santini NO; Halm EA
    Cancer; 2016 Feb; 122(3):456-63. PubMed ID: 26535565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fecal occult blood and flexible sigmoidoscopy screening for colorectal cancer: modeling the impact on colonoscopy requirements and cancer detection rates.
    Olynyk JK; Platell CF; Collett JA
    J Gastroenterol Hepatol; 2001 Apr; 16(4):389-92. PubMed ID: 11354276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Overview of current modalities of colorectal cancer screening].
    Kajzrlíková IM; Vítek P
    Vnitr Lek; 2016 Apr; 62(4):308-11. PubMed ID: 27250609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rolling-out Screening Volume Affecting Compliance Rate and Waiting Time of FIT-based Colonoscopy.
    Jen HH; Hsu CY; Chen SL; Yen AM; Chiu SY; Fann JC; Lee YC; Wu MS; Hsu WF; Peng SM; Chen HH; Chiu HM
    J Clin Gastroenterol; 2018 Oct; 52(9):821-827. PubMed ID: 29095416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recommendations raise workload issues for colon cancer screening.
    Twombly R
    J Natl Cancer Inst; 2004 Mar; 96(5):348-50. PubMed ID: 14996852
    [No Abstract]   [Full Text] [Related]  

  • 48. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas.
    Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Sakaguchi K; Shiratori Y
    Am J Gastroenterol; 2007 Oct; 102(10):2259-64. PubMed ID: 17617203
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
    Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
    Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy.
    Woo HY; Mok RS; Park YN; Park DI; Sung IK; Sohn CI; Park H
    Clin Biochem; 2005 Apr; 38(4):395-9. PubMed ID: 15766742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Are repeated fecal immunochemical tests effective for detecting advanced colorectal neoplasia in first-degree relatives of patients with colorectal cancers?].
    Chun J; Im JP
    Korean J Gastroenterol; 2015 Jan; 65(1):66-9. PubMed ID: 25751892
    [No Abstract]   [Full Text] [Related]  

  • 52. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of COVID-19 on colorectal cancer early diagnosis pathway: retrospective cohort study.
    Abdellatif M; Salama Y; Alhammali T; Eltweri AM
    Br J Surg; 2021 Apr; 108(4):e146-e147. PubMed ID: 33792641
    [No Abstract]   [Full Text] [Related]  

  • 54. The Need for an Integrated Patient Navigation Pathway to Improve Access to Colonoscopy After Positive Fecal Immunochemical Testing: A Safety-Net Hospital Experience.
    Thamarasseril S; Bhuket T; Chan C; Liu B; Wong RJ
    J Community Health; 2017 Jun; 42(3):551-557. PubMed ID: 27796633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resource implications for a population-based colorectal cancer screening program in Canada: a study of the impact on colonoscopy capacity and costs in London, Ontario.
    Lau A; Gregor JC
    Can J Gastroenterol; 2007 Jun; 21(6):371-7. PubMed ID: 17571171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer.
    Robertson DJ; Lee JK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Lieberman D; Levin TR; Rex DK
    Gastrointest Endosc; 2017 Jan; 85(1):2-21.e3. PubMed ID: 27769516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.